Acadia Pharmaceuticals (ACAD) Inventory (2016 - 2026)

Acadia Pharmaceuticals' Inventory history runs 11 years deep, the most recent figure standing at $31.6 million for Q1 2026.

• On a quarterly basis, Inventory rose 37.59% year-over-year to $31.6 million in Q1 2026; TTM through Mar 2026 was $31.6 million, a 37.59% increase from a year earlier, with the FY2025 full-year figure at $34.7 million, up 57.96% from the prior year.
• Inventory eased to $31.6 million in Q1 2026 per ACAD's latest filing, from $34.7 million in the prior quarter.
• Across five years, Inventory topped out at $71.5 million in Q2 2024 and bottomed at $5.8 million in Q3 2022.
• The 5-year median for Inventory is $22.9 million (2025), against an average of $27.0 million.
• Across the five-year window, Inventory surged 916.18% in 2024 and tumbled 63.48% in 2025, its largest moves.
• Year by year, Inventory stood at $6.6 million in 2022, then jumped by 439.77% to $35.8 million in 2023, then sank by 38.72% to $21.9 million in 2024, then soared by 57.96% to $34.7 million in 2025, then slipped by 8.93% to $31.6 million in 2026.
• Per Business Quant, the three latest ACAD Inventory figures stand at $31.6 million (Q1 2026), $34.7 million (Q4 2025), and $29.1 million (Q3 2025).